Olaparib is already available for the treatment of cancer and is also being investigated as a potential therapy for pulmonary arterial hypertension (Clinical Trial No.: NCT03782818), although these applications focus on DNA damage and repair features of PARP1/ARTD1 inhibition. This evidence concerns the gene PARP1 and pulmonary arterial hypertension.